Skorney believes that the high placebo response in AbbVie’s trials might indicate poor trial ... Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Continuity Biosciences, LLC, a new bioscience company dedicated to developing and commercializing cutting-edge technologies ...

BeiGene may lose the lawsuit to AbbVie over Brukinsa and start to pay royalties ... which is proportionally higher than the moaty pharmaceutical peers. We do not see sufficient promising late-stage ...

The team includes Bob Whitehead (Executive Chairman), a veteran in the bioscience field known for successful strategic exits and initiatives; Ramakrishna Venugopalan, PhD (Co-Founder & CEO), a former ...

For reasons that aren’t entirely clear, pharmaceutical stocks are often out of favor with ... However, as a company like ...

Which is the best pick right now? Here's my favorite Dividend King to buy in November. AbbVie, therefore, inherits the rich dividend history of its parent. In September, Abbott announced its 52nd ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell/File Photo The number of sexually transmitted ...

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...